Mark Purcell
Stock Analyst at Morgan Stanley
(1.05)
# 3,605
Out of 4,847 analysts
5
Total ratings
50%
Success rate
-9.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $116.70 | -2.31% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $49.19 | +11.81% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $41.66 | +5.62% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $71.93 | +18.17% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $72.83 | +64.77% | 1 | Jan 23, 2024 | |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $116.70
Upside: -2.31%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $49.19
Upside: +11.81%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $41.66
Upside: +5.62%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $71.93
Upside: +18.17%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $72.83
Upside: +64.77%